Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.
The company’s pipeline includes several promising candidates:
- Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
- Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
- Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
- Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
- Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).
I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.
Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.
For the latest updates and detailed information, visit the official website at I-Mab Biopharma.
I-Mab (Nasdaq: IMAB) has announced the dosing of the first patient in a Phase 3 clinical trial for lemzoparlimab, a CD47 antibody, targeting higher-risk myelodysplastic syndrome (MDS) in China. This trial, a pivotal step in the development of novel therapies for MDS, aims to evaluate the safety and efficacy of lemzoparlimab in combination with azacitidine (AZA) compared to AZA alone. MDS predominantly affects older adults, and current treatments often lead to suboptimal outcomes. Lemzoparlimab represents a potential breakthrough, as it may become the first CD47-targeting therapy approved in China. I-Mab's commitment to addressing the unmet medical needs of MDS patients is underscored by this milestone.
HI-Bio announced positive Phase 2 results for felzartamab, a monoclonal antibody targeting CD38+ plasma cells, aimed at treating Primary Membranous Nephropathy (PMN). Two studies, M-PLACE and NewPLACE, demonstrated significant reductions in pathogenic aPLA2R autoantibodies, which are linked to PMN. In M-PLACE, 31 patients showed a median reduction of 45% in aPLA2R levels as early as one week, with substantial sustainable responses observed. The drug also led to proteinuria remissions in patients resistant to current therapies. HI-Bio plans to advance felzartamab into late-stage development, targeting PMN and other autoimmune diseases. This disease affects over 36,000 patients in the U.S. with no approved treatments currently available.
I-Mab (Nasdaq: IMAB) announced its financial results for 2022, reporting a net loss of RMB2.41 billion (US$349.7 million), slightly worsening from RMB2.33 billion in 2021. The company's total net revenue dropped to RMB-221.6 million (US$-32.1 million) due to a significant non-cash accounting treatment. However, I-Mab achieved thirteen key clinical milestones, including positive data readouts for several assets and a strong cash position of RMB3.5 billion (US$514.2 million), sufficient to fund operations for three years. The company plans to submit potential biologics license applications for key assets by late 2023 or early 2024.
I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, will announce its financial results for the full year ended December 31, 2022 on March 31, 2023. The report will be released before the market opens, followed by a conference call for investors and analysts at 8:15 a.m. EST. I-Mab focuses on the discovery and development of novel biologics, with over 10 candidates in its pipeline. The company aims to bring innovative medicines to patients globally, leveraging both internal research and partnerships.
I-Mab (Nasdaq: IMAB) announced two poster presentations showcasing data on lemzoparlimab at the 64th ASH Annual Meeting from December 10-13, 2022, in New Orleans. The presentations will cover biomarker analyses from a phase 2 study involving lemzoparlimab and azacitidine for myelodysplastic syndrome and preclinical data on leveraging CD47 and CD38 immuno-oncology targets for multiple myeloma treatment. The research indicates potential clinical benefits and therapeutic mechanisms, especially in high-risk populations, underscoring I-Mab's commitment to advancing lemzoparlimab's clinical development.
I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced new preclinical data for its assets lemzoparlimab and uliledlimab, to be presented at the 37th SITC Annual Meeting in Boston from November 8-12, 2022. The presentations will include enhanced activity against HER2 expressing tumors and novel immune modulatory mechanisms of uliledlimab. Abstracts will be available on the SITC website on November 7, 2022. I-Mab continues its commitment to developing innovative biologics for cancer therapies and has multiple ongoing clinical studies.
I-Mab (Nasdaq: IMAB) announced the successful completion of an End-of-Phase 2 meeting with China's National Medical Products Administration (NMPA), leading to approval for a Phase 3 trial of lemzoparlimab combined with azacitidine for higher-risk myelodysplastic syndrome (HR-MDS). The encouraging Phase 2 results, presented at ESMO Congress 2022, showed that the combination therapy was effective and safe. The company aims to submit a biologic license application in China following this trial.
I-Mab announced positive results from its Phase 2 clinical trial of lemzoparlimab combined with azacitidine (AZA) for treating higher-risk myelodysplastic syndrome (HR-MDS) at the ESMO Congress 2022. The overall response rate (ORR) was 86.7% for patients treated over 6 months, while the complete response (CR) rate reached 40%. Notably, lemzoparlimab did not require priming dosing and exhibited no unexpected safety signals. A Phase 3 trial is planned to further evaluate this promising combination therapy.
FAQ
What is the current stock price of I-Mab (IMAB)?
What is the market cap of I-Mab (IMAB)?
What is I-Mab's core focus?
What are some key products in I-Mab's pipeline?
Where are I-Mab's main operations located?
What recent strategic move has I-Mab made?
What is felzartamab?
Who is I-Mab collaborating with on givastomig?
How does I-Mab fund its operations and research?
What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?
What is I-Mab's approach to drug development?
How can investors stay updated on I-Mab's progress?
